retatrutide joint pain shows substantial weight loss and relief in obesity and OA patients | Andrew J. Sauer, MD posted on the topic Retatrutide delivers on improving knee

Gastroenterology 132 (6), 21312157

No direct head-to-head trial exists between Retatrutide and either medication yet, though Phase 3 trials may include such comparisons

The researchers says this body of evidence increases the need to study GLP-1 drugs as a potential approach to addressing persistent obesity in the US, which currently affects about 42 percent of the U.S

Read Verified Experiences With Health Journey GLP-1 Booster Frequently Asked Questions About Health Journey GLP-1 Booster Reviews and Complaints Consumers researching reviews and complaints often share the same concerns

Another positive finding was seen in 60 patients with BED and T2DM when dulaglutide, which is not currently licensed for obesity, was compared with placebo at 12 weeks 222

Originally FDA-approved to treat diabetes, they turned out to produce notable weight loss as well, reducing appetite, increasing metabolism and fat burning, and lowering BMI